Immuno-Oncology LBP Combination Preclinical Evaluation Service

Preclinical Evidence Planning for Immuno-Oncology LBP Combinations

Immuno-oncology biotech teams are increasingly exploring live biotherapeutic products (LBPs) as microbiome-directed partners for checkpoint inhibitor programs. The challenge is converting a promising strain hypothesis into interpretable preclinical evidence: tumor response, immune-cell activity, cytokine changes, colonization dynamics, and microbiome signatures must be organized within one coherent study plan that can guide candidate selection without overextending early budgets.

For checkpoint inhibitor and oncology biotech groups, the most useful package is not a standalone tumor curve, but a connected view of efficacy, mechanism, and microbial behavior across treatment arms. Creative Biolabs provides an immuno-oncology LBP combination preclinical evaluation service that helps teams design tumor-model studies, execute immune and microbiome readouts, and package results for confident candidate prioritization, partnership discussion, and next-stage development planning.

Core Evaluation Focus

•LBP and checkpoint inhibitor combination study design
•Tumor growth, survival, and response-pattern analysis
•Immune profiling, cytokine panels, and microbiome correlation

Immuno-Oncology LBP Combination Preclinical Evaluation Services

Our service is structured to answer the practical questions that determine whether an LBP candidate can support an immuno-oncology combination strategy: which tumor model is appropriate, which checkpoint inhibitor schedule should be tested, which immune endpoints are decision-relevant, and how microbiome changes should be linked to antitumor activity.

Tumor Model and Combination Study Design

Study frameworks that connect LBP exposure to checkpoint inhibitor response.

Creative Biolabs supports syngeneic and microbiome-sensitive oncology models for evaluating live biotherapeutic candidates with anti-PD-1, anti-PD-L1, anti-CTLA-4, or client-defined checkpoint inhibitor approaches. We help define tumor cell line selection, implantation strategy, microbiome conditioning logic, LBP route and schedule, antibody dosing window, group structure, and sample collection points.

The output is a study design that avoids underpowered exploratory testing and instead captures interpretable comparisons between vehicle, LBP alone, checkpoint inhibitor alone, and combination arms.

Antitumor Efficacy Readouts

We monitor tumor growth kinetics, endpoint tumor burden, response distribution, survival-related metrics where appropriate, and gross pathology observations. Data are organized to distinguish additive effects from true combination signals and to identify whether the LBP contributes measurable value beyond checkpoint blockade alone.

Immune Cell Profiling

Tumor, spleen, lymph node, and blood samples can be profiled by flow cytometry, immunohistochemistry, or multiplexed panels to assess CD8⁺ T cells, CD4⁺ T cells, Tregs, myeloid populations, activation/exhaustion markers, and tumor-infiltrating immune-cell balance.

Cytokine and Mechanism Panels

We evaluate immune mediator changes such as IFN-gamma, IL-2, TNF-alpha, IL-10, CXCL10, and other client-prioritized markers. These readouts help clarify whether the candidate supports T-cell recruitment, inflammatory remodeling, antigen-presentation logic, or broader immune normalization.

Microbiome Correlation and Candidate Prioritization

For LBP teams, a tumor-size curve is rarely enough. We pair efficacy endpoints with fecal, intestinal, or tumor-associated microbiome profiling when appropriate, enabling correlation between candidate exposure, community shifts, beneficial taxa, functional pathway signals, and immune response patterns.

This integrated analysis helps teams decide whether to advance a strain, refine formulation or dose schedule, add a mechanistic assay, or compare additional consortia before committing to larger translational studies.

Strain Tracking

qPCR, sequencing, or culture-based support for persistence and exposure interpretation.

Community Shifts

Microbiome composition and diversity analysis before, during, and after combination treatment.

Mechanistic Signals

Associations between taxa, pathways, cytokines, and tumor immune remodeling.

Decision Mapping

Clear interpretation of whether the candidate supports further IO-combination development.

Preclinical Immuno-Oncology LBP Study Deliverables

Deliverables are designed for teams that need more than raw animal-study results. We organize the evidence into a decision-ready package that supports candidate comparison, mechanism discussion, and internal development planning.

Deliverable	Included Content	Program Value
Combination Study Protocol Framework	Tumor model selection, group design, LBP dosing logic, checkpoint inhibitor schedule, sampling map, and endpoint rationale.	Aligns scientific goals with an executable preclinical study plan.
Efficacy and Immune Readout Report	Tumor kinetics, response comparisons, immune-cell profiles, cytokine results, histology-supported observations, and statistical summaries.	Clarifies whether the LBP adds measurable value to checkpoint inhibitor treatment.
Microbiome-Response Correlation Summary	Sequencing or targeted microbial readout interpretation linked to tumor response, immune markers, and candidate exposure.	Connects microbial biology to decision-making rather than treating microbiome data as a separate appendix.
Next-Study Gap Map	Recommended follow-up assays, confirmatory model options, dose/schedule refinement, mechanism hypotheses, and risk areas requiring clarification.	Helps teams move from exploratory data to focused development action.

LBP and Checkpoint Inhibitor Combination Evaluation Workflow

Our workflow keeps model selection, biology, and reporting connected from the first design discussion through final interpretation.

1

Program Intake

Review strain rationale, checkpoint strategy, tumor indication, prior in vitro data, and target mechanism.

2

Model Build

Select tumor model, animal conditioning approach, treatment arms, and sample timing.

3

Study Execution

Run LBP administration, checkpoint inhibitor treatment, tumor monitoring, and biological sampling.

4

Immune and Microbiome Analysis

Profile immune cells, cytokines, tissue markers, microbial composition, and candidate-associated shifts.

5

Evidence Package

Deliver integrated interpretation, study figures, data tables, and recommended next steps.

Published Data Supporting Immuno-Oncology LBP Combination Evaluation

Recent research using an antibiotic-disrupted colorectal cancer mouse model evaluated Lactobacillus rhamnosus Probio-M9 with anti-PD-1 treatment and tracked tumor growth, survival, fecal metagenomes, and microbiome recovery. The study compared probiotic-only, anti-PD-1-only, combination, and control groups, making it directly relevant to LBP developers that need to separate single-agent effects from combination-specific activity and interpret microbial changes alongside tumor outcomes.

The image illustrates a practical evidence structure for IO-LBP work: treatment timing, tumor monitoring, and survival analysis are presented together, while the article links response patterns to microbiome restoration. That type of integrated design helps teams define whether a candidate supports checkpoint inhibitor activity, which immune questions deserve deeper follow-up, and how microbiome data should inform the next study. Creative Biolabs can provide related preclinical combination evaluation support for LBP teams developing immuno-oncology strategies.

Tumor model response under probiotic and anti-PD-1 treatment. (OA Literature) — Fig.1 Effect of host microbiota modulation on antitumor therapy by anti-programmed cell death protein-1 (PD-1) antibody. ^1,2

Why Creative Biolabs for Immuno-Oncology LBP Combination Studies

Creative Biolabs brings together microbiology, oncology model execution, immune assay design, and microbiome analytics so clients can evaluate combination biology within one coordinated preclinical framework.

Integrated IO-LBP Design

Combination arms, LBP exposure, checkpoint inhibitor timing, and sampling are designed as one connected study.

Mechanism-Oriented Readouts

Immune-cell profiling and cytokine panels are selected to explain response biology, not simply populate a report.

Microbiome-Aware Interpretation

Microbial composition, strain exposure, and functional signals are interpreted alongside tumor and immune endpoints.

Decision-Ready Reporting

Final outputs clarify candidate value, follow-up gaps, and practical next experiments for early-stage teams.

Recommended Services for IO-LBP Programs

Teams preparing an immuno-oncology LBP package often benefit from pairing combination studies with cancer-model efficacy testing, immune modulation assays, and mechanism-of-action screening.

Frequently Asked Questions

This service is suited for LBP teams exploring microbiome-directed support for checkpoint inhibitor response, especially programs that need animal-model evidence, immune mechanism data, or microbiome-response correlation before selecting a lead strain or advancing a combination concept.

Yes. A typical design can include vehicle, LBP alone, checkpoint inhibitor alone, and LBP-plus-checkpoint inhibitor arms. Additional dose, schedule, or comparator arms can be added when the study question requires broader candidate ranking.

Depending on the model and sample plan, endpoints can include tumor-infiltrating lymphocyte profiles, CD8⁺ T-cell activation, Treg balance, myeloid populations, cytokine panels, chemokine markers, and tissue-level immune staining.

Yes. We can integrate fecal or tissue-associated microbiome readouts with tumor growth, immune-cell, and cytokine data to identify response-associated microbial patterns and generate follow-up hypotheses for strain optimization.

Useful inputs include the candidate strain or consortium description, prior functional data, intended tumor indication, preferred checkpoint inhibitor class, formulation or dosing constraints, and any immune or microbiome endpoints already considered important by the project team.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video

References

Gao, Guangqi, et al. "Adjunctive probiotic Lactobacillus rhamnosus Probio-M9 administration enhances the effect of anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota." Frontiers in Immunology 12 (2021): 772532. https://doi.org/10.3389/fimmu.2021.772532
Distributed under Open Access license CC BY 4.0, without modification.